Hydroxyurea pharmacokinetics and precision dosing in low-resource settings

Introduction: Hydroxyurea is effective disease-modifying treatment for sickle cell anemia (SCA). Escalation to maximum tolerated dose (MTD) achieves superior benefits without additional toxicities, but requires dose adjustments with serial monitoring. Pharmacokinetic (PK)-guided dosing can predict a...

Descripción completa

Detalles Bibliográficos
Autores principales: Smart, Luke R., Charles, Mwesige, McElhinney, Kathryn E., Dong, Min, Power-Hays, Alexandra, Howard, Thad, Vinks, Alexander A., Ambrose, Emmanuela E., Ware, Russell E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267409/
https://www.ncbi.nlm.nih.gov/pubmed/37325474
http://dx.doi.org/10.3389/fmolb.2023.1130206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267409/
https://www.ncbi.nlm.nih.gov/pubmed/37325474
http://dx.doi.org/10.3389/fmolb.2023.1130206

Ejemplares similares